SCHEMBL9957429

SCHEMBL9957429

CC(C)(C)OC(=O)NCCNC(=O)c1ccc2c(c1)C(CO)c1ccccc1-2

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PTPRC P08575 2/20 0.47
MALT1 Q9UDY8 1/20 0.44
PDK2 Q15119 3/20 0.40
DGAT1 O75907 1/20 0.40
KCNA5 P22460 1/20 0.40
ACACB O00763 2/20 0.40
ACACA Q13085 2/20 0.40
PDCD1 Q15116 1/20 0.39
CD274 Q9NZQ7 1/20 0.39
GABRA5 P31644 1/20 0.39
BCHE P06276 1/20 0.38
EGFR P00533 1/20 0.38
KMT2A Q03164 1/20 0.37
IDO1 P14902 1/20 0.37
ALDH1A1 P00352 1/20 0.37
HPGD P15428 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29773956 0.85 OPRM1 (0.41) PTPRCPDK2DGAT1BCHEIDO1
SCHEMBL9956879 0.85 OPRM1 (0.41) PTPRCPDK2DGAT1BCHEIDO1
SCHEMBL9956437 0.81 KCNA5 (0.47) MALT1PDK2KCNA5PDCD1CD274
SCHEMBL24439884 0.81 KMT2A (0.43) MALT1PDK2PDCD1CD274KMT2A
SCHEMBL2601917 0.79 PTPRC (0.68) PTPRCMALT1KCNA5KMT2AALDH1A1
SCHEMBL2997209 0.78 EPHX2 (0.46) IDO1
SCHEMBL15462855 0.77 BCHE (0.38) PTPRCBCHEKMT2A
SCHEMBL5557644 0.77 KMT2A (0.60) MALT1BCHEKMT2AIDO1
SCHEMBL12341218 0.76 L3MBTL1 (0.50) PDK2KMT2AALDH1A1HPGDSMN1; SMN2
SCHEMBL284764 0.76 SMN1; SMN2 (0.55) MALT1ACACBACACABCHEKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11406618-B2 Polymer-des-ethyl sunitinib conjugates NEKTAR THERAPEUTICS (US) 2022-08-09 US disclosed
US-20190142798-A1 POLYMER-DES-ETHYL SUNITINIB CONJUGATES NEKTAR THERAPEUTICS 2019-05-16 US disclosed
US-20190142798-A1 POLYMER-DES-ETHYL SUNITINIB CONJUGATES NEKTAR THERAPEUTICS 2019-05-16 US disclosed
US-10220020-B2 Polymer-des-ethyl sunitinib conjugates NEKTAR THERAPEUTICS (US) 2019-03-05 US disclosed
US-10220020-B2 Polymer-des-ethyl sunitinib conjugates NEKTAR THERAPEUTICS (US) 2019-03-05 US disclosed
EP-2654797-B1 POLYMER-DES-ETHYL SUNITINIB CONJUGATES NEKTAR THERAPEUTICS (US) 2017-11-08 EP disclosed
EP-2654797-B1 POLYMER-DES-ETHYL SUNITINIB CONJUGATES NEKTAR THERAPEUTICS (US) 2017-11-08 EP disclosed
US-20140039030-A1 POLYMER-DES-ETHYL SUNITINIB CONJUGATES NEKTAR THERAPEUTICS (US) 2014-02-06 US disclosed
US-20140039030-A1 POLYMER-DES-ETHYL SUNITINIB CONJUGATES NEKTAR THERAPEUTICS (US) 2014-02-06 US disclosed
EP-2654797-A1 POLYMER-DES-ETHYL SUNITINIB CONJUGATES Nektar Therapeutics (US) 2013-10-30 EP disclosed
WO-2012088522-A1 POLYMER-DES-ETHYL SUNITINIB CONJUGATES NEKTAR THERAPEUTICS (US) 2012-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10220020-B2 Polymer-des-ethyl sunitinib conjugates KDR, FLT4, FLT1 PTPRC 794/4885MALT1 1439/4885PDK2 1526/4885
US-11406618-B2 Polymer-des-ethyl sunitinib conjugates KDR, FLT4, FLT1 PTPRC 794/4885MALT1 1439/4885PDK2 1526/4885
US-20140039030-A1 POLYMER-DES-ETHYL SUNITINIB CONJUGATES KDR, FLT4, FLT1 PTPRC 794/4885MALT1 1439/4885PDK2 1526/4885
US-20190142798-A1 POLYMER-DES-ETHYL SUNITINIB CONJUGATES KDR, FLT4, FLT1 PTPRC 794/4885MALT1 1439/4885PDK2 1526/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.